Kangchen Pharmaceutical (603590.SH) subsidiary plans to participate in Ullman's E-round financing with 150 million yuan.

Zhongtong Finance APP news, Kangchen Pharmaceuticals (603590.SH) issued an announcement on July 21, 2025. The company's wholly-owned subsidiary Kangchen Pharmaceuticals (Hong Kong) Co., Ltd. (referred to as "Kangchen Hong Kong") and the target of the transaction, Nuance Biotech (referred to as "Yurui Cayman") and its subsidiaries, jointly signed a "Stock Subscription Agreement". Kangchen Hong Kong intends to invest 150 million yuan to participate in the E-round financing of Yurui Cayman, subscribing to 38.4395 million shares of E-round preferred stock newly issued by Yurui Cayman. The funds raised in this round of financing will be used for Yurui Cayman's business expansion, capital expenditures, working capital, etc., to support its application for listing of innovative drugs, and to meet other operational funding needs.